<?xml version='1.0' encoding='utf-8'?>
<document id="28971607"><sentence text="Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide."><entity charOffset="65-75" id="DDI-PubMed.28971607.s1.e0" text="ledipasvir" /><entity charOffset="76-86" id="DDI-PubMed.28971607.s1.e1" text="sofosbuvir" /><entity charOffset="91-102" id="DDI-PubMed.28971607.s1.e2" text="rilpivirine" /><entity charOffset="103-116" id="DDI-PubMed.28971607.s1.e3" text="emtricitabine" /><entity charOffset="117-138" id="DDI-PubMed.28971607.s1.e4" text="tenofovir alafenamide" /><pair ddi="false" e1="DDI-PubMed.28971607.s1.e0" e2="DDI-PubMed.28971607.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28971607.s1.e0" e2="DDI-PubMed.28971607.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28971607.s1.e0" e2="DDI-PubMed.28971607.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s1.e0" e2="DDI-PubMed.28971607.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s1.e0" e2="DDI-PubMed.28971607.s1.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s1.e1" e2="DDI-PubMed.28971607.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28971607.s1.e1" e2="DDI-PubMed.28971607.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s1.e1" e2="DDI-PubMed.28971607.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s1.e1" e2="DDI-PubMed.28971607.s1.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s1.e2" e2="DDI-PubMed.28971607.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s1.e2" e2="DDI-PubMed.28971607.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s1.e2" e2="DDI-PubMed.28971607.s1.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s1.e3" e2="DDI-PubMed.28971607.s1.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s1.e3" e2="DDI-PubMed.28971607.s1.e4" /></sentence><sentence text="The drug-drug interaction (DDI) potential between the fixed-dose combinations of ledipasvir/sofosbuvir 90/400 mg for hepatitis C virus and emtricitabine/rilpivirine/tenofovir alafenamide (TAF) 200/25/25 mg for HIV was evaluated in a randomized, open-label, single-center, multiple-dose, 3-way, 6-sequence, crossover Phase 1 study in 42 healthy subjects"><entity charOffset="81-91" id="DDI-PubMed.28971607.s2.e0" text="ledipasvir" /><entity charOffset="92-102" id="DDI-PubMed.28971607.s2.e1" text="sofosbuvir" /><entity charOffset="139-152" id="DDI-PubMed.28971607.s2.e2" text="emtricitabine" /><entity charOffset="153-164" id="DDI-PubMed.28971607.s2.e3" text="rilpivirine" /><entity charOffset="165-186" id="DDI-PubMed.28971607.s2.e4" text="tenofovir alafenamide" /><entity charOffset="188-191" id="DDI-PubMed.28971607.s2.e5" text="TAF" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e0" e2="DDI-PubMed.28971607.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e0" e2="DDI-PubMed.28971607.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e0" e2="DDI-PubMed.28971607.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e0" e2="DDI-PubMed.28971607.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e0" e2="DDI-PubMed.28971607.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e0" e2="DDI-PubMed.28971607.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e1" e2="DDI-PubMed.28971607.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e1" e2="DDI-PubMed.28971607.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e1" e2="DDI-PubMed.28971607.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e1" e2="DDI-PubMed.28971607.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e1" e2="DDI-PubMed.28971607.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e2" e2="DDI-PubMed.28971607.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e2" e2="DDI-PubMed.28971607.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e2" e2="DDI-PubMed.28971607.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e2" e2="DDI-PubMed.28971607.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e3" e2="DDI-PubMed.28971607.s2.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e3" e2="DDI-PubMed.28971607.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e3" e2="DDI-PubMed.28971607.s2.e5" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e4" e2="DDI-PubMed.28971607.s2.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s2.e4" e2="DDI-PubMed.28971607.s2.e5" /></sentence><sentence text=" Emtricitabine/rilpivirine/TAF had no relevant effect on the pharmacokinetic parameters of maximum concentration [Cmax ] and area under the concentration versus time curve over the dosing interval [AUCtau ] for ledipasvir, sofosbuvir, and the metabolites GS-566500 and GS-331007"><entity charOffset="1-14" id="DDI-PubMed.28971607.s3.e0" text="Emtricitabine" /><entity charOffset="15-26" id="DDI-PubMed.28971607.s3.e1" text="rilpivirine" /><entity charOffset="27-30" id="DDI-PubMed.28971607.s3.e2" text="TAF" /><entity charOffset="211-221" id="DDI-PubMed.28971607.s3.e3" text="ledipasvir" /><entity charOffset="223-233" id="DDI-PubMed.28971607.s3.e4" text="sofosbuvir" /><entity charOffset="255-264" id="DDI-PubMed.28971607.s3.e5" text="GS-566500" /><entity charOffset="269-278" id="DDI-PubMed.28971607.s3.e6" text="GS-331007" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e0" e2="DDI-PubMed.28971607.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e0" e2="DDI-PubMed.28971607.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e0" e2="DDI-PubMed.28971607.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e0" e2="DDI-PubMed.28971607.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e0" e2="DDI-PubMed.28971607.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e0" e2="DDI-PubMed.28971607.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e0" e2="DDI-PubMed.28971607.s3.e6" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e1" e2="DDI-PubMed.28971607.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e1" e2="DDI-PubMed.28971607.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e1" e2="DDI-PubMed.28971607.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e1" e2="DDI-PubMed.28971607.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e1" e2="DDI-PubMed.28971607.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e1" e2="DDI-PubMed.28971607.s3.e6" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e2" e2="DDI-PubMed.28971607.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e2" e2="DDI-PubMed.28971607.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e2" e2="DDI-PubMed.28971607.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e2" e2="DDI-PubMed.28971607.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e2" e2="DDI-PubMed.28971607.s3.e6" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e3" e2="DDI-PubMed.28971607.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e3" e2="DDI-PubMed.28971607.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e3" e2="DDI-PubMed.28971607.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e3" e2="DDI-PubMed.28971607.s3.e6" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e4" e2="DDI-PubMed.28971607.s3.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e4" e2="DDI-PubMed.28971607.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e4" e2="DDI-PubMed.28971607.s3.e6" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e5" e2="DDI-PubMed.28971607.s3.e5" /><pair ddi="false" e1="DDI-PubMed.28971607.s3.e5" e2="DDI-PubMed.28971607.s3.e6" /></sentence><sentence text=" Ledipasvir/sofosbuvir had no effect on the Cmax and AUCtau for rilpivirine and emtricitabine"><entity charOffset="1-11" id="DDI-PubMed.28971607.s4.e0" text="Ledipasvir" /><entity charOffset="12-22" id="DDI-PubMed.28971607.s4.e1" text="sofosbuvir" /><entity charOffset="64-75" id="DDI-PubMed.28971607.s4.e2" text="rilpivirine" /><entity charOffset="80-93" id="DDI-PubMed.28971607.s4.e3" text="emtricitabine" /><pair ddi="false" e1="DDI-PubMed.28971607.s4.e0" e2="DDI-PubMed.28971607.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28971607.s4.e0" e2="DDI-PubMed.28971607.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28971607.s4.e0" e2="DDI-PubMed.28971607.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s4.e0" e2="DDI-PubMed.28971607.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s4.e1" e2="DDI-PubMed.28971607.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28971607.s4.e1" e2="DDI-PubMed.28971607.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s4.e1" e2="DDI-PubMed.28971607.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s4.e2" e2="DDI-PubMed.28971607.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s4.e2" e2="DDI-PubMed.28971607.s4.e3" /></sentence><sentence text=" The Cmax and AUCtau of tenofovir, the major metabolite of TAF, were increased by 62% and 75%, respectively"><entity charOffset="24-33" id="DDI-PubMed.28971607.s5.e0" text="tenofovir" /><entity charOffset="59-67" id="DDI-PubMed.28971607.s5.e1" text="TAF" /><pair ddi="false" e1="DDI-PubMed.28971607.s5.e0" e2="DDI-PubMed.28971607.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28971607.s5.e0" e2="DDI-PubMed.28971607.s5.e1" /></sentence><sentence text=" However, the resulting absolute tenofovir exposures were markedly lower than the historical tenofovir exposures following tenofovir disoproxil fumarate (TDF) and, as such, were not considered to be clinically relevant"><entity charOffset="33-42" id="DDI-PubMed.28971607.s6.e0" text="tenofovir" /><entity charOffset="93-102" id="DDI-PubMed.28971607.s6.e1" text="tenofovir" /><entity charOffset="123-152" id="DDI-PubMed.28971607.s6.e2" text="tenofovir disoproxil fumarate" /><entity charOffset="154-157" id="DDI-PubMed.28971607.s6.e3" text="TDF" /><pair ddi="false" e1="DDI-PubMed.28971607.s6.e0" e2="DDI-PubMed.28971607.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28971607.s6.e0" e2="DDI-PubMed.28971607.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28971607.s6.e0" e2="DDI-PubMed.28971607.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s6.e0" e2="DDI-PubMed.28971607.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s6.e1" e2="DDI-PubMed.28971607.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28971607.s6.e1" e2="DDI-PubMed.28971607.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s6.e1" e2="DDI-PubMed.28971607.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s6.e2" e2="DDI-PubMed.28971607.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s6.e2" e2="DDI-PubMed.28971607.s6.e3" /></sentence><sentence text=" In contrast, additional adverse effect monitoring is recommended upon coadministration of ledipasvir and TDF due to elevated tenofovir exposures resulting from the DDI"><entity charOffset="91-101" id="DDI-PubMed.28971607.s7.e0" text="ledipasvir" /><entity charOffset="126-135" id="DDI-PubMed.28971607.s7.e1" text="tenofovir" /><entity charOffset="106-114" id="DDI-PubMed.28971607.s7.e2" text="TDF" /><pair ddi="false" e1="DDI-PubMed.28971607.s7.e0" e2="DDI-PubMed.28971607.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28971607.s7.e0" e2="DDI-PubMed.28971607.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s7.e0" e2="DDI-PubMed.28971607.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28971607.s7.e2" e2="DDI-PubMed.28971607.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s7.e2" e2="DDI-PubMed.28971607.s7.e1" /></sentence><sentence text=" This difference is explained by the fact that TAF 25 mg results in markedly lower (~90%) plasma tenofovir exposure compared to TDF 300 mg"><entity charOffset="97-106" id="DDI-PubMed.28971607.s8.e0" text="tenofovir" /><entity charOffset="47-55" id="DDI-PubMed.28971607.s8.e1" text="TAF" /><entity charOffset="128-136" id="DDI-PubMed.28971607.s8.e2" text="TDF" /><pair ddi="false" e1="DDI-PubMed.28971607.s8.e1" e2="DDI-PubMed.28971607.s8.e1" /><pair ddi="false" e1="DDI-PubMed.28971607.s8.e1" e2="DDI-PubMed.28971607.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28971607.s8.e1" e2="DDI-PubMed.28971607.s8.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s8.e0" e2="DDI-PubMed.28971607.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28971607.s8.e0" e2="DDI-PubMed.28971607.s8.e2" /></sentence><sentence text=" Ledipasvir/sofosbuvir and emtricitabine/rilpivirine/TAF were generally well tolerated when administered alone or in combination"><entity charOffset="1-11" id="DDI-PubMed.28971607.s9.e0" text="Ledipasvir" /><entity charOffset="12-22" id="DDI-PubMed.28971607.s9.e1" text="sofosbuvir" /><entity charOffset="27-40" id="DDI-PubMed.28971607.s9.e2" text="emtricitabine" /><entity charOffset="41-52" id="DDI-PubMed.28971607.s9.e3" text="rilpivirine" /><entity charOffset="53-63" id="DDI-PubMed.28971607.s9.e4" text="TAF" /><pair ddi="false" e1="DDI-PubMed.28971607.s9.e0" e2="DDI-PubMed.28971607.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28971607.s9.e0" e2="DDI-PubMed.28971607.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28971607.s9.e0" e2="DDI-PubMed.28971607.s9.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s9.e0" e2="DDI-PubMed.28971607.s9.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s9.e0" e2="DDI-PubMed.28971607.s9.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s9.e1" e2="DDI-PubMed.28971607.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28971607.s9.e1" e2="DDI-PubMed.28971607.s9.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s9.e1" e2="DDI-PubMed.28971607.s9.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s9.e1" e2="DDI-PubMed.28971607.s9.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s9.e2" e2="DDI-PubMed.28971607.s9.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s9.e2" e2="DDI-PubMed.28971607.s9.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s9.e2" e2="DDI-PubMed.28971607.s9.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s9.e3" e2="DDI-PubMed.28971607.s9.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s9.e3" e2="DDI-PubMed.28971607.s9.e4" /></sentence><sentence text=" HIV/hepatitis C virus-coinfected patients can coadminister ledipasvir/sofosbuvir and emtricitabine/rilpivirine/TAF without dosage adjustments"><entity charOffset="60-70" id="DDI-PubMed.28971607.s10.e0" text="ledipasvir" /><entity charOffset="71-81" id="DDI-PubMed.28971607.s10.e1" text="sofosbuvir" /><entity charOffset="86-99" id="DDI-PubMed.28971607.s10.e2" text="emtricitabine" /><entity charOffset="100-111" id="DDI-PubMed.28971607.s10.e3" text="rilpivirine" /><entity charOffset="112-122" id="DDI-PubMed.28971607.s10.e4" text="TAF" /><pair ddi="false" e1="DDI-PubMed.28971607.s10.e0" e2="DDI-PubMed.28971607.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28971607.s10.e0" e2="DDI-PubMed.28971607.s10.e1" /><pair ddi="false" e1="DDI-PubMed.28971607.s10.e0" e2="DDI-PubMed.28971607.s10.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s10.e0" e2="DDI-PubMed.28971607.s10.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s10.e0" e2="DDI-PubMed.28971607.s10.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s10.e1" e2="DDI-PubMed.28971607.s10.e1" /><pair ddi="false" e1="DDI-PubMed.28971607.s10.e1" e2="DDI-PubMed.28971607.s10.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s10.e1" e2="DDI-PubMed.28971607.s10.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s10.e1" e2="DDI-PubMed.28971607.s10.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s10.e2" e2="DDI-PubMed.28971607.s10.e2" /><pair ddi="false" e1="DDI-PubMed.28971607.s10.e2" e2="DDI-PubMed.28971607.s10.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s10.e2" e2="DDI-PubMed.28971607.s10.e4" /><pair ddi="false" e1="DDI-PubMed.28971607.s10.e3" e2="DDI-PubMed.28971607.s10.e3" /><pair ddi="false" e1="DDI-PubMed.28971607.s10.e3" e2="DDI-PubMed.28971607.s10.e4" /></sentence><sentence text="" /></document>